Roche saw increased competition from biosimilar and generic medicines, with primary patents for multiple older products expiring

Worldwide revenue (in millions CHF) for the second quarter (Q2) of 2025, the first half (H1) of 2025, and 2024 for the top 10 of Roche's marketed drugs.

(Please use a modern browser to see the interactive version of this visualization)

Chart: © Phalguni Deswal, Drug and Device World (www.druganddeviceworld.com)Source: Roche's financial disclosuresDownload imageCreated with Datawrapper